Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX: PBT) covers the month of November 2011. The registrant is a foreign private issuer based in Australia. The filing serves as a notice under Section 708A(5) of the Corporations Act regarding the issuance of securities without prior disclosure to investors.
Key Financial Metrics and Capital Structure
The filing details a specific capital raise event rather than providing comprehensive financial statements for a reporting period.
- Securities Issued: 2,736,530 Ordinary Fully Paid Shares.
- Issue Date: November 25, 2011.
- Total Proceeds: AUD$466,847.
- Post-Issue Capital: 285,396,913 Ordinary Shares quoted on the ASX.
- Outstanding Options: The filing lists multiple classes of unlisted options (e.g., PBTAB, PBTAD, PBTAI) with varying exercise prices and expiry dates, totaling over 20 million options across various plans.
Note: The filing text does not provide clear values for revenue, profit, cash flow, operating margins, debt levels, or liquidity ratios.
Material Changes
The primary material change is the increase in the company's share capital by 2,736,530 shares. These new shares rank pari passu with existing ordinary shares from the date of allotment. The company has applied to the ASX for quotation of these additional securities.
Guidance, Outlook, and Management Commentary
Purpose of Issue: Management stated the proceeds are intended to fund the company's current clinical development, research programs, and working capital.
Dividend Policy: The dividend policy on the increased capital remains unchanged.
Risks and Contingencies: The filing includes standard warranties to the ASX regarding the legality of the issue and compliance with the Corporations Act. No specific new risks or contingencies were disclosed in this text.
Investor Verification Checklist
- Verify the exact issue price per share by dividing the total proceeds (AUD$466,847) by the number of shares issued (2,736,530).
- Confirm the current trading status of the newly issued shares on the ASX.
- Review the terms of the outstanding unlisted options (exercise prices and expiry dates) to assess potential future dilution.
- Check subsequent filings for updates on the utilization of the raised funds for clinical development.